Boron

Human and animal data indicate that boron plays a meaningful role in osteogenesis and the maintenance of bone mineral density, especially in postmenopausal women. In a 2024 pilot study of 66 Jordanian women with established osteoporosis, higher dietary boron intake (2.3–4.8 mg/day, mean 3.3 mg/day) was strongly and positively correlated with bone mineral density, while showing a negative correlation with serum calcium, suggesting improved skeletal retention of calcium rather than hypercalcemia. No significant associations were found with serum vitamin D, BMI, or other lifestyle factors, underscoring an independent role of boron intake in bone status. Earlier metabolic ward research demonstrated that supplementing 3 mg/day of boron after a period of low intake (~0.25 mg/day) markedly reduced urinary losses of calcium and magnesium and increased serum estradiol, changes interpreted as protective against bone demineralization in postmenopausal women. Reviews of the broader literature conclude that boron deficiency impairs bone development and regeneration, while adequate boron supports cortical bone strength and trabecular micro-architecture.

Boron has been investigated as a supportive treatment for osteoarthritis and general joint health, with several lines of evidence converging on symptomatic benefit at low doses. A double-blind placebo-controlled trial in 20 patients with osteoarthritis reported that 6 mg/day of boron led to significant clinical improvement: 50% of participants receiving boron experienced marked relief of pain and discomfort compared with only 10% in the placebo group, and observational data show lower boron levels in bone and synovial fluid among those with arthritis. Epidemiologic comparisons suggest that populations with habitual boron intakes below 1 mg/day have an estimated arthritis incidence of 20–70%, whereas areas where intakes are typically 3–10 mg/day report incidences of 0–10%, implying a possible protective threshold. More recently, a randomized, double-blind pilot trial using calcium fructoborate (a boron-containing complex found in plants) in middle-aged adults with knee osteoarthritis demonstrated short-term reductions in pain and improvements in physical function over just two weeks, alongside favorable changes in inflammatory markers, without serious adverse events.

Controlled feeding studies and mechanistic work indicate that boron helps fine-tune mineral metabolism, particularly of calcium, magnesium, and phosphorus, in synergy with vitamin D. In a metabolic ward study of 12 postmenopausal women, adding 3 mg/day of boron to a previously low-boron diet dramatically reduced urinary excretion of calcium and magnesium and, in those on low magnesium diets, also reduced phosphorus loss, changes that would be expected to favor bone mineral retention. The same supplementation protocol increased circulating 17β-estradiol and testosterone levels, providing hormonal support for calcium conservation. Animal experiments and human observational data reviewed by Pizzorno and others show that boron deficiency impairs the synthesis and action of active vitamin D (calcitriol), whereas boron supplementation stimulates bone growth in vitamin D-deficient animals and has been associated with increased serum 25-hydroxyvitamin D3 in vitamin D-deficient humans. Functional nutrition analyses suggest that variations in boron intake may partly explain why individuals respond so differently to the same dose of vitamin D, as boron appears to reduce vitamin D breakdown and improve the bioavailability of calcium and magnesium.

Boron appears to influence steroid hormone metabolism, particularly in postmenopausal women consuming low-boron diets, though the clinical implications require cautious interpretation. In the metabolic ward study of 12 women aged 48–82 years, supplementing 3 mg/day of boron after 119 days on a very low-boron intake (~0.25 mg/day) significantly elevated serum 17β-estradiol and testosterone, with more pronounced effects under low-magnesium conditions, suggesting that boron status intersects with both mineral and hormonal physiology. Reviews of human and animal studies report that boron intake affects the presence or function of hormones including vitamin D, estrogen, thyroid hormone, insulin, and progesterone, and that depleted boron in animals is linked to fertility problems and developmental anomalies. Functional medicine case reports and practitioner summaries describe improvements in menopausal symptoms, PMS, and vitality when boron intake is optimized, though these observations are not yet supported by large randomized human trials. Because boron can raise estrogen levels, experts recommend caution with supplemental doses in individuals with hormone-sensitive conditions, even as low-dose supplementation may be useful for selected postmenopausal women with low dietary intake.

Human crossover trials in older adults suggest that boron plays a functional role in brain electrophysiology and cognitive performance, with low intake associated with malnutrition-like effects on neural activity. In three within-subject studies, healthy older men and women were fed diets providing either approximately 0.25 mg or 3.25 mg of boron per 2000 kcal per day, and their EEG spectral profiles and performance on cognitive and psychomotor tests were compared. When participants consumed the low-boron diet, EEG recordings showed increased low-frequency activity and reduced higher-frequency activity, a pattern commonly seen in general malnutrition and heavy metal toxicity, indicating suboptimal neuronal function. On neuropsychological tasks, low boron intake was associated with significantly poorer performance on measures of manual dexterity, eye–hand coordination, attention, perception, encoding and short-term memory, and long-term memory across the different study designs. These findings, together with observational data, led the authors to conclude that boron likely contributes to human brain function and may be essential for maintaining optimal cognitive performance, particularly in the context of aging.

Boron and boron-containing complexes have demonstrated anti-inflammatory effects in both animal models and human osteoarthritis trials, with reductions in key markers such as C-reactive protein (CRP), TNF-α, IL-1β, and fibrinogen. A double-blind pilot study of calcium fructoborate supplementation in middle-aged adults with knee osteoarthritis found that 15 days of intake delivering 1.5–6 mg/day of boron significantly lowered systemic inflammatory biomarkers, including CRP, ESR, and fibrinogen, compared with placebo, alongside improvements in pain and physical function. In rat models of chronic and granulomatous inflammation, boron administered at 3.0 and 6.0 mg/kg reduced serum TNF-α, IL-1β, and hs-CRP in a dose-dependent manner, with higher doses producing effects comparable to dexamethasone and combinations of boron with dexamethasone yielding the greatest suppression. Clinical reviews summarize that boron supplementation in humans can reduce hs-CRP and TNF-α by 30–50% in some contexts and increase the activity of antioxidant enzymes such as superoxide dismutase, catalase, and glutathione peroxidase, thereby attenuating oxidative stress that fuels chronic inflammation and pain. These properties underpin its exploration as a supportive agent in arthritis and other low-grade inflammatory conditions.

Although direct clinical trials on infection outcomes are scarce, boron’s ability to reduce systemic inflammation, modulate vitamin D metabolism, and enhance antioxidant enzyme activity suggests an indirect supportive role in immune function. Functional analyses note that individuals with higher baseline inflammation are at increased risk of infection and hospitalization, and boron supplementation has been associated with 30–50% reductions in inflammatory markers like CRP in some clinical settings, particularly at doses as low as 1.5 mg/day of boron delivered as calcium fructoborate. Mechanistic work shows that boron can reduce the breakdown of vitamin D, leading to paradoxical increases in 25-hydroxyvitamin D levels even during seasonal declines, and that boron depletion impairs immune-related processes such as wound healing, in which immune cells orchestrate tissue repair. Animal studies demonstrate that boron raises the activity of antioxidant enzymes involved in microbial killing and oxidative defense, complementing the roles of magnesium, copper, zinc, and selenium in immune resilience. Based on these converging lines of evidence, low-dose boron is sometimes used as part of nutrient strategies aimed at optimizing immune competence, though robust randomized infection trials are still needed.

Boron-containing compounds are emerging as promising agents in wound care, primarily supported by preclinical studies and mechanistic reviews that highlight their anti-inflammatory, antimicrobial, antioxidant, and pro-proliferative actions. A 2024 comprehensive review of boron in wound healing concluded that boron modulates inflammatory responses by inhibiting pro-inflammatory cytokines and promoting timely resolution of inflammation, a critical step in the transition from the inflammatory to the proliferative phase of wound repair. Boron exhibits antimicrobial activity against a range of pathogens commonly implicated in chronic and infected wounds, thereby lowering the risk of persistent infection and supporting re-epithelialization. Its antioxidant capacity helps protect cells within the wound bed from oxidative stress, which otherwise impairs healing, and boron stimulates cell proliferation and migration, including fibroblasts and keratinocytes, to promote tissue regeneration and closure. While these mechanisms are compelling and align with boron’s broader roles in inflammation and mineral metabolism, clinical data in humans are still limited, and most applications currently involve topical or biomaterial-based boron formulations rather than oral supplements.

Epidemiologic data suggest that higher dietary boron intake may be associated with a reduced risk of prostate cancer, although evidence is preliminary and observational. An analysis of NHANES III compared 95 men with prostate cancer to 8,720 male controls and found that those in the highest quartile of boron intake had about half the odds of prostate cancer (adjusted odds ratio 0.46, 95% CI 0.21–0.98) compared with those in the lowest quartile, with a borderline significant trend across quartiles. Experimental and mechanistic studies summarized in reviews indicate that boron and boronated compounds can exert antiproliferative and chemopreventive effects in various cancers, including prostate, cervical, and lung cancers, as well as lymphomas, and may ameliorate adverse effects of some chemotherapeutic agents. Nevertheless, these anticancer actions are largely based on in vitro work, animal models, and pharmaceutical boron compounds rather than simple nutritional supplementation, and the hormonal effects of boron (such as increasing estradiol) warrant caution in those with estrogen-sensitive malignancies. At present, boron intake should be viewed as a possible supportive factor within an overall healthy dietary pattern, rather than a standalone cancer-preventive intervention.

Short-term supplementation with calcium fructoborate has shown modest favorable changes in lipid markers in adults with knee osteoarthritis, suggesting potential metabolic benefits beyond joint and inflammatory effects. In the randomized, double-blind pilot trial in Romania, middle-aged participants with primary knee osteoarthritis received various doses of calcium fructoborate (providing 1.5–6 mg/day of boron) or placebo for 15 days. In addition to significant reductions in inflammatory markers and improvements in pain and physical performance, the boron-containing groups exhibited slight but consistent shifts in lipid parameters, including total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides, compared with placebo, although the magnitude of these changes was small and the study was not primarily powered for cardiovascular outcomes. Mechanistic reasoning suggests that by improving inflammation, oxidative stress, and mineral metabolism, boron may contribute indirectly to more favorable metabolic profiles, but dedicated cardiometabolic trials are lacking. Thus, any metabolic benefits of boron should be considered secondary and exploratory at this stage.